Helen Schiltz

Helen Schiltz serves as Chief Operating Officer at OncoC4, Inc.. OncoC4, Inc. operates in the pharmaceuticals sector with approximately 63.0 employees. The company is headquartered in Rockville, Maryland. OncoC4, Inc. generates annual revenue of 2000000.0.

Industry & Role Insights

• • MessageCEO tracks 1,288 executives in the pharmaceuticals sector.
• • 2,221 executive contacts are available in Maryland.
• • Our database includes 201,469 c suite-level executives.

Cloudflare DNS Outlook Microsoft Office 365 CloudFlare Hosting Mobile Friendly reCAPTCHA AddThis Google Font API WordPress.org Joomla Nginx Remote AI

pharmaceutical manufacturing immunotherapy cancer treatment pd-1 vegf ctla-4 siglec cd24 bispecific antibodies monoclonal antibodies antibody-drug conjugates car t-cell therapies neurodegenerative diseases alzheimer's disease tumor microenvironment immune checkpoints immunotherapy resistance antibody therapies clinical pipeline cancer-specific antibodies solid tumors hematologic malignancies clinical trials targeted therapy immune response cell-cell interaction antitumor activity ph-sensitive antibodies immune-related adverse events oncology cancer research immune modulation phase 1 trial phase 2 trial phase 3 trial therapeutic strategies immune escape safety profile efficacy drug development novel targets clinical efficacy antibody design treatment modalities cellular signaling cancer cells therapeutic platform chronic diseases novel checkpoints pharmaceuticals medical health care health wellness & fitness hospital & health care

YM

Yathendra Madineni Chief Executive Officer at 4C Pharma Solutions

RB

Ronan Brown Chief Operating Officer at 4G Clinical

HK

Hitoshi Kamiya Chief Executive Officer at A2 Healthcare Corporation

LJ

Lars Jensen CEO at A-apoteket

TL

Tien Lee CEO at Aardvark Therapeutics, Inc.

Outreach Guidance — pharmaceuticals Sector

Executives like Helen Schiltz in the pharmaceuticals sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at OncoC4, Inc..

Helen Schiltz's Position in the MessageCEO Database

• •Helen Schiltz is 1 of 1 verified executive contact we track at OncoC4, Inc..
• •1,240 verified executive contacts in pharmaceuticals are in the MessageCEO database.
• •2,100 verified executive contacts in Maryland are in the database.
• •4 verified contacts work at pharmaceuticals companies in the 63.0 employee range (same size as OncoC4, Inc.).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Helen Schiltz directly?

Helen Schiltz's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Operating Officer at OncoC4, Inc.. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Helen Schiltz work for?

Helen Schiltz is Chief Operating Officer at OncoC4, Inc., a company in the pharmaceuticals sector with 63.0 employees. The company is based in Rockville, Maryland.

Can I pitch or sell to Helen Schiltz?

As Chief Operating Officer at OncoC4, Inc., Helen Schiltz is a key decision-maker in the pharmaceuticals sector. MessageCEO Pro gives you verified email to reach Helen Schiltz directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Helen Schiltz in?

Helen Schiltz works in the pharmaceuticals industry as Chief Operating Officer at OncoC4, Inc.. MessageCEO provides verified contact information for executives across all major industries.

Is Helen Schiltz's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Helen Schiltz's profile is kept up-to-date with the latest available information.

Last updated: July 23, 2026